High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between Fcγrllla polymorphism

International Immunology

Volumn 24, Issue 8, 2012, Pages 477-483

  Mishima, Yuji ^a   Terui, Yasuhito ^a,b   Mishima, Yuko ^a,b   Kuniyoshi, Ryoko ^a   Matsusaka, Satoshi ^a,b   Mikuniya, Mariko ^a   Kojima, Kiyotsugu ^c   Hatake, Kiyohiko ^a,b  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c OLYMPUS CORPORATION   (Japan)

Author keywords

Fc receptor polymorphism; Timelapse imaging

Indexed keywords

CD16 ANTIGEN; RITUXIMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BLOOD SAMPLING; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT SYSTEM; DRUG CYTOTOXICITY; EFFECTOR CELL; EXPRESSION VECTOR; GENETIC ANALYSIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LEUKEMIA CELL LINE; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NORMAL HUMAN; PLASMID; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CELL LINE; COMPLEMENT ACTIVATION; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; KILLER CELLS, NATURAL; MICROSCOPY, CONFOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IGG; TRANSFECTION;

EID: 84865071316     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxs048     Document Type: Article

References (20)

1. Anderson, D. R., Grillo-Lopez, A., Varns, C., Chambers, K. S. and Hanna, N. 1997. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem. Soc. Trans. 25:705.
2. Golay, J., Zaffaroni, L., Vaccari, T. et al. 2000. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95:3900.
3. Fischer, L., Penack, O., Gentilini, C. et al. 2006. The antilymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Exp. Hematol. 34:753.
4. Byrd, J. C., Kitada, S., Flinn, I. W. et al. 2002. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 99:1038.
5. Mishima, Y., Sugimura, N., Matsumoto-Mishima, Y. et al. 2009. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy. Clin. Cancer Res. 15:3624.
6. Duesberg, U., Schneiders, A. M., Flieger, D., Inchauspe, G., Sauerbruch, T. and Spengler, U. 2001. Natural cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) is not impaired in patients suffering from chronic hepatitis C. J. Hepatol. 35:650.
7. Beum, P. V., Lindorfer, M. A. and Taylor, R. P. 2008. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. J. Immunol. 181:2916.
8. Dall'Ozzo, S., Tartas, S., Paintaud, G. et al. 2004. Rituximabdependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 64:4664.
9. Kennedy, A. D., Beum, P. V., Solga, M. D. et al. 2004. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J. Immunol. 172:3280.
10. Nishio, M., Endo, T., Fujimoto, K. et al. 2009. FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. Eur. J. Haematol. 82:143.
11. Yagita, M., Huang, C. L., Umehara, H. et al. 2000. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 14:922.
12. Preithner, S., Elm, S., Lippold, S. et al. 2006. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol. Immunol. 43:1183.
13. McLaughlin, P., Grillo-Lopez, A. J., Link, B. K. et al. 1998. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a fourdose treatment program. J. Clin. Oncol. 16:2825.
14. Lenz, G., Dreyling, M., Hoster, E. et al. 2005. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J. Clin. Oncol. 23:1984.
15. Coiffier, B. 2003. Monoclonal antibodies combined to chemotherapy for the treatment of patients with lymphoma. Blood Rev. 17:25.
16. Cartron, G., Dacheux, L., Salles, G. et al. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754.
17. Bello, C. and Sotomayor, E. M. 2007. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am. Soc. Hematol. Educ. Program: 2007:233.
18. van Meerten, T., van Rijn, R. S., Hol, S., Hagenbeek, A. and Ebeling, S. B. 2006. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin. Cancer Res. 12:4027.
19. Treon, S. P., Mitsiades, C., Mitsiades, N. et al. 2001. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J. Immunother. 24:263.
20. Wang, S. Y., Racila, E., Taylor, R. P. and Weiner, G. J. 2008. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood 111:1456.